Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium lactate infusion in GLUT1 deficiency syndrome
NL-OMON48362Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sodium lactate in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS), sponsored by Radboud University Medical Center. Primary endpoint: Change in epileptic discharges on EEG. Started May 2022; status: active, not recruiting.
02
Drugs
Sodium lactate
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NL-OMON48362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48362.